神经退行性疾病中的TREM2:机制和治疗潜力
Ling Li1, Xiaoxiao Zheng1, Hongyue Ma1
1Department of Neurology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing 102218, China.
Cells
|September 13, 2025
概括
神经炎症驱动神经退行性疾病,如阿尔茨海默氏症. 本综述探讨了微质上释受体表达在骨髓细胞2 (TREM2) 的关键调节器和潜在的治疗点.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 神经退行性疾病 (阿尔茨海默病,帕金森病,ALS) 是一个主要的健康问题.
- 慢性神经炎症,涉及小质细胞,显著促进疾病的进展.
- 导致神经元损失和认知衰退的机制尚未完全理解.
研究的目的:
- 在神经退行性疾病中,审查在骨髓细胞2 (TREM2) 上表达的触发受体的功能.
- 评估TREM2作为这些疾病的潜在治疗点.
- 为未来治疗策略的制定提供信息.
主要方法:
- 关于神经退行症中TREM2功能研究的文献综述.
- 分析TREM2在微质激活和免疫反应中的作用.
- 检查TREM2在细胞分裂,突触修剪和新陈代谢中的参与.
主要成果:
- 在中枢神经系统中,TREM2在微质上高度表达.
- TREM2 调节关键的微质功能,包括细胞和新陈代谢.
- 功能障碍的TREM2信号可能会加剧神经炎症和疾病进展.
结论:
- 在神经退行性疾病中,TREM2在调节神经炎症方面发挥着至关重要的作用.
- 准TREM2为阿尔茨海默病,帕金森病和ALS提供了一个有希望的治疗途径.
- 对TREM2调制的进一步研究可能会导致新的治疗方法.
相关概念视频
Enzyme-linked Receptors
86.1K
Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
86.1K
Alzheimer's Disease: Treatment
827
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
827
Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
Role of Neurotransmitters in Memory
2.5K
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
2.5K
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
834
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
834


